Azad Engineering Ltd AZAD

Summary

Azad Engineering makes high-precision forged and machined airfoils, blades, engine assemblies and actuators sold to GE Aviation, Honeywell, Eaton, Boeing, Rolls-Royce, Pratt & Whitney and others — alongside a larger Energy and Oil & Gas business (GE, Mitsubishi, Siemens as customers there) that, per available disclosure, still generates roughly 80% of revenue. CARE Ratings' independent assessment places Azad among just four global players in its particular niche, with PBILDT margins consistently above 25% (39.09% in FY26) and a ₹6,500 crore order book — a genuinely rare capability set.

The concern is entirely about price, not the business. At a trailing P/E of 132x, Azad already trades above every disclosed analyst target this research could find: S&P Global's consensus of seven analysts averaged ₹2,534, Univest's most recent published target was ₹2,550, and Trendlyne's two-analyst average was ₹1,900 — all below the ₹2,849 the stock traded at in this research. Working capital has also elongated materially (344 days in FY26 versus 287 in FY25) and gearing nearly doubled (0.18x to 0.30x) funding new capacity.

Net: SELL, anchored to the disclosed sell-side consensus rather than an independently constructed multiple, since genuine analyst coverage exists here and largely agrees the stock is ahead of itself.

• One of only four comparable global players, per CARE Ratings' independent assessment — a genuinely scarce competitive set, not marketing language.
• Margins that back up the scarcity claim. PBILDT margin has expanded every year disclosed, reaching 39.1% in FY26 — exceptional for a forged-components manufacturer.
• A ₹6,500cr order book providing 5-6 years of revenue visibility per CARE, split roughly ₹3,966cr energy and ₹1,834cr aerospace.
• Real customer diversification across both aerospace and energy — Boeing, Rolls-Royce, Pratt & Whitney on one side; GE, Mitsubishi, Siemens, BHEL, Toshiba on the other.
• Actively expanding capacity — three to four new dedicated manufacturing facilities commissioned in FY26 for global OEMs.

• The stock trades above every disclosed analyst target this research could find. Three independent trackers (S&P Global consensus, Univest, Trendlyne) all show targets below the current price, by 11-33% depending on the source.
• Aerospace is the minority of the business. Roughly 80% of revenue still comes from the Energy and Oil & Gas verticals — the "aerospace" framing understates how much of Azad's fortunes ride on industrial gas-turbine and power-sector demand.
• Working capital has elongated materially. 344 days in FY26 versus 287 in FY25, per CARE, driven by inventory build for products under development and newly-commissioned facilities.
• Leverage nearly doubled in one year. Gearing rose from 0.18x to 0.30x funding debt-financed capex.
• Contradictory secondary-source claims on governance red flags (one aggregator flags a "red" verdict citing pledge-type concerns; another claims a clean record) — this research could not resolve the dispute against a primary filing.
• A combined Chairman/CEO role held by the founding promoter is a governance structure worth noting, even though the board otherwise meets independence norms.

• Working-capital-cycle trend in FY27 — whether the FY26 elongation reverses as new facilities ramp.
• Resolution of the contradictory governance-screen claims against a primary BSE filing.
• Further analyst target revisions as FY27 results are published.

• Valuation risk (dominant). Every disclosed analyst target found sits below the current price.
• Energy/O&G cyclicality, given its ~80% share of revenue.
• Leverage and working-capital risk from the debt-funded capacity build-out.

Genuine sell-side coverage exists for Azad, and it clusters below the current price. We anchor to that disclosed consensus rather than construct an independent multiple:

We set our target at the more recent, larger-sample S&P Global consensus figure (₹2,534) rather than the simple average, since it is both the most current and the broadest-sampled data point found.

Source: CARE Ratings press release (22 Jun 2026, full text); screener.in (11 Sep 2026); S&P Global/Univest/Trendlyne consensus trackers (secondary aggregation, not independently verified against original broker notes).